IBDEI15W ; ; 12-MAY-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 12, 2016
 Q:'DIFQR(358.4)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.4,673,0)
 ;;=ANXIETY DISORDERS^2^58
 ;;^UTILITY(U,$J,358.4,674,0)
 ;;=BIPOLAR DISORDERS^3^58
 ;;^UTILITY(U,$J,358.4,675,0)
 ;;=NEUROCOGNITIVE DISORDERS^17^58
 ;;^UTILITY(U,$J,358.4,676,0)
 ;;=DEPRESSIVE DISORDERS^7^58
 ;;^UTILITY(U,$J,358.4,677,0)
 ;;=DISSOCIATIVE DISORDERS ^9^58
 ;;^UTILITY(U,$J,358.4,678,0)
 ;;=FEEDING & EATING DISORDERS^12^58
 ;;^UTILITY(U,$J,358.4,679,0)
 ;;=EDUCATIONAL/OCCUPATIONAL PROBLEMS^10^58
 ;;^UTILITY(U,$J,358.4,680,0)
 ;;=GENDER DYSPHORIA^14^58
 ;;^UTILITY(U,$J,358.4,681,0)
 ;;=HOUSING/ECONOMIC PROBLEMS^15^58
 ;;^UTILITY(U,$J,358.4,682,0)
 ;;=MEDICATION-INDUCED MOVEMENT DISORDERS^16^58
 ;;^UTILITY(U,$J,358.4,683,0)
 ;;=OBSESSIVE-COMPULSIVE & RELATED DISORDERS^19^58
 ;;^UTILITY(U,$J,358.4,684,0)
 ;;=PERSONAL HX & CURRENT CIRCUMSTANCES^22^58
 ;;^UTILITY(U,$J,358.4,685,0)
 ;;=COUNSELING/MEDICAL ADVICE^5^58
 ;;^UTILITY(U,$J,358.4,686,0)
 ;;=SOCIAL ENVIRONMENT PROBLEMS^29^58
 ;;^UTILITY(U,$J,358.4,687,0)
 ;;=PARAPHILIC DISORDERS^21^58
 ;;^UTILITY(U,$J,358.4,688,0)
 ;;=PERSONALITY DISORDERS^23^58
 ;;^UTILITY(U,$J,358.4,689,0)
 ;;=CRIME/LEGAL SYSTEM PROBLEMS^6^58
 ;;^UTILITY(U,$J,358.4,690,0)
 ;;=PSYCHOSOCIAL/PERSONAL/ENVIRONMENTAL^24^58
 ;;^UTILITY(U,$J,358.4,691,0)
 ;;=RELATIONAL PROBLEMS^25^58
 ;;^UTILITY(U,$J,358.4,692,0)
 ;;=SCHIZOPHRENIA/OTH PSYCHOTIC DISORDERS^26^58
 ;;^UTILITY(U,$J,358.4,693,0)
 ;;=SEXUAL DYSFUNCTIONS^27^58
 ;;^UTILITY(U,$J,358.4,694,0)
 ;;=SLEEP-WAKE DISORDERS^28^58
 ;;^UTILITY(U,$J,358.4,695,0)
 ;;=SUBSTANCE USE DISORDER-ALCOHOL^31^58
 ;;^UTILITY(U,$J,358.4,696,0)
 ;;=SUBSTANCE USE DISORDER-CANNABIS^33^58
 ;;^UTILITY(U,$J,358.4,697,0)
 ;;=SUBSTANCE USE DISORDER-HALLUCINOGEN^34^58
 ;;^UTILITY(U,$J,358.4,698,0)
 ;;=SUBSTANCE USE DISORDER-OPIOID^36^58
 ;;^UTILITY(U,$J,358.4,699,0)
 ;;=SUBSTANCE USE DISORDER-SEDATIVE/HYPNOTIC^37^58
 ;;^UTILITY(U,$J,358.4,700,0)
 ;;=SUBSTANCE USE DISORDER-TOBACCO^39^58
 ;;^UTILITY(U,$J,358.4,701,0)
 ;;=TRAUMA/STRESSOR-RELATED DISORDERS^42^58
 ;;^UTILITY(U,$J,358.4,702,0)
 ;;=SUBSTANCE USE DISORDER-INHALANT^35^58
 ;;^UTILITY(U,$J,358.4,703,0)
 ;;=CLINICAL RESEARCH PROGRAM^4^58
 ;;^UTILITY(U,$J,358.4,704,0)
 ;;=SOMATIC SYMPTOM & RELATED DISORDERS^30^58
 ;;^UTILITY(U,$J,358.4,705,0)
 ;;=DISRUPTIVE,IMPULSE-CONTROL DISORDERS^8^58
 ;;^UTILITY(U,$J,358.4,706,0)
 ;;=ELIMINATION DISORDERS^11^58
 ;;^UTILITY(U,$J,358.4,707,0)
 ;;=GAMBLING DISORDER^13^58
 ;;^UTILITY(U,$J,358.4,708,0)
 ;;=OTHER MENTAL DISORDERS^20^58
 ;;^UTILITY(U,$J,358.4,709,0)
 ;;=NEURODEVELOPMENTAL DISORDERS^18^58
 ;;^UTILITY(U,$J,358.4,710,0)
 ;;=SUBSTANCE USE DISORDER-CAFFEINE^32^58
 ;;^UTILITY(U,$J,358.4,711,0)
 ;;=SUICIDAL IDEATIONS^41^58
 ;;^UTILITY(U,$J,358.4,712,0)
 ;;=SUBSTANCE USE DISORDER-UNKNOWN SUBSTANCE^40^58
 ;;^UTILITY(U,$J,358.4,713,0)
 ;;=SUBSTANCE USE DISORDER-STIMULANTS^38^58
 ;;^UTILITY(U,$J,358.4,714,0)
 ;;=NEW PATIENT HOME VISIT^2^59
 ;;^UTILITY(U,$J,358.4,715,0)
 ;;=ESTAB PATIENT HOME VISIT^1^59
 ;;^UTILITY(U,$J,358.4,716,0)
 ;;=TEAM CONFERENCE^8^60
 ;;^UTILITY(U,$J,358.4,717,0)
 ;;=PROCEDURE CODE^6^60
 ;;^UTILITY(U,$J,358.4,718,0)
 ;;=EDUCATION/TRAINING^1^60
 ;;^UTILITY(U,$J,358.4,719,0)
 ;;=IMMUNIZATIONS^2^60
 ;;^UTILITY(U,$J,358.4,720,0)
 ;;=OTH PREVENTIVE MEDICINE SVCS^3^60
 ;;^UTILITY(U,$J,358.4,721,0)
 ;;=SKIN TEST^7^60
 ;;^UTILITY(U,$J,358.4,722,0)
 ;;=PREVENTIVE MED-EST PT^4^60
 ;;^UTILITY(U,$J,358.4,723,0)
 ;;=PREVENTIVE MED-NEW PT^5^60
 ;;^UTILITY(U,$J,358.4,724,0)
 ;;=PC COMMON DIAGNOSES^1^61
 ;;^UTILITY(U,$J,358.4,725,0)
 ;;=ADMINISTRATIVE TOPICS^2^61
 ;;^UTILITY(U,$J,358.4,726,0)
 ;;=ANGINA^3^61
 ;;^UTILITY(U,$J,358.4,727,0)
 ;;=ATHEROSCLEROSIS^4^61
 ;;^UTILITY(U,$J,358.4,728,0)
 ;;=CARDIOVASCULAR^5^61
 ;;^UTILITY(U,$J,358.4,729,0)
 ;;=DERMATOLOGY^9^61
 ;;^UTILITY(U,$J,358.4,730,0)
 ;;=EAR DISORDERS^10^61
 ;;^UTILITY(U,$J,358.4,731,0)
 ;;=EENT^11^61
 ;;^UTILITY(U,$J,358.4,732,0)
 ;;=ENDOCRINE/METABOLIC^12^61
 ;;^UTILITY(U,$J,358.4,733,0)
 ;;=EYE DISORDERS^13^61
 ;;^UTILITY(U,$J,358.4,734,0)
 ;;=EYE INJURY^14^61
 ;;^UTILITY(U,$J,358.4,735,0)
 ;;=GASTROENTEROLOGY^15^61
 ;;^UTILITY(U,$J,358.4,736,0)
 ;;=GU/RENAL^16^61
 ;;^UTILITY(U,$J,358.4,737,0)
 ;;=HEADACHE^17^61
 ;;^UTILITY(U,$J,358.4,738,0)
 ;;=HEART FAILURE^18^61
 ;;^UTILITY(U,$J,358.4,739,0)
 ;;=HEART VALVE DISEASE^19^61
 ;;^UTILITY(U,$J,358.4,740,0)
 ;;=HEMATOLOGY/ONCOLOGY^20^61
 ;;^UTILITY(U,$J,358.4,741,0)
 ;;=HISTORY OF ILLNESS^21^61
 ;;^UTILITY(U,$J,358.4,742,0)
 ;;=INFECTIOUS DISEASE^22^61
 ;;^UTILITY(U,$J,358.4,743,0)
 ;;=LIVER DISEASE^23^61
 ;;^UTILITY(U,$J,358.4,744,0)
 ;;=MENTAL HEALTH^25^61
 ;;^UTILITY(U,$J,358.4,745,0)
 ;;=MOVEMENT DISORDERS^26^61
 ;;^UTILITY(U,$J,358.4,746,0)
 ;;=MUSCULOSKELETAL^27^61
 ;;^UTILITY(U,$J,358.4,747,0)
 ;;=NEUROLOGY^28^61
 ;;^UTILITY(U,$J,358.4,748,0)
 ;;=PAIN^29^61
 ;;^UTILITY(U,$J,358.4,749,0)
 ;;=PREVENTIVE HEALTH^30^61
 ;;^UTILITY(U,$J,358.4,750,0)
 ;;=PULMONARY^31^61
 ;;^UTILITY(U,$J,358.4,751,0)
 ;;=SEXUAL TRAUMA^32^61
 ;;^UTILITY(U,$J,358.4,752,0)
 ;;=SIGNS,SYMPTOMS,CONDITIONS^33^61
 ;;^UTILITY(U,$J,358.4,753,0)
 ;;=SPRAIN/STRAIN-INITIAL ENCOUNTER^34^61
 ;;^UTILITY(U,$J,358.4,754,0)
 ;;=SUBSTANCE DISORDERS^35^61
 ;;^UTILITY(U,$J,358.4,755,0)
 ;;=VARICOSE VEINS^36^61
 ;;^UTILITY(U,$J,358.4,756,0)
 ;;=WOMEN'S HEALTH^37^61
 ;;^UTILITY(U,$J,358.4,757,0)
 ;;=WOUNDS-INITIAL ENCOUNTER^38^61
 ;;^UTILITY(U,$J,358.4,758,0)
 ;;=COMA^7^61
 ;;^UTILITY(U,$J,358.4,759,0)
 ;;=CAUSES OF INJURY^6^61
 ;;^UTILITY(U,$J,358.4,760,0)
 ;;=DEMENTIA^8^61
 ;;^UTILITY(U,$J,358.4,761,0)
 ;;=LONG TERM CURRENT DRUG THERAPY^24^61
 ;;^UTILITY(U,$J,358.4,762,0)
 ;;=SPECIAL SERVICES^7^62
 ;;^UTILITY(U,$J,358.4,763,0)
 ;;=TREATMENT^8^62
 ;;^UTILITY(U,$J,358.4,764,0)
 ;;=MISCELLANEOUS^5^62
 ;;^UTILITY(U,$J,358.4,765,0)
 ;;=IMMUNIZATIONS^3^62
 ;;^UTILITY(U,$J,358.4,766,0)
 ;;=CHEMO ADMINISTRATION^1^62
 ;;^UTILITY(U,$J,358.4,767,0)
 ;;=CHEMO DRUGS^2^62
 ;;^UTILITY(U,$J,358.4,768,0)
 ;;=OTHER DRUGS^6^62
 ;;^UTILITY(U,$J,358.4,769,0)
 ;;=MGMT L/T ANTICOAG TX^4^62
 ;;^UTILITY(U,$J,358.4,770,0)
 ;;=NEW PATIENT^2^63
 ;;^UTILITY(U,$J,358.4,771,0)
 ;;=ESTABLISHED PATIENT^1^63
 ;;^UTILITY(U,$J,358.4,772,0)
 ;;=CONSULTATIONS^3^63
 ;;^UTILITY(U,$J,358.4,773,0)
 ;;=POST OP^4^63
 ;;^UTILITY(U,$J,358.4,774,0)
 ;;=ANEMIA^1^64
 ;;^UTILITY(U,$J,358.4,775,0)
 ;;=BREAST & GYN NEOPLASMS^2^64
 ;;^UTILITY(U,$J,358.4,776,0)
 ;;=COAGULATION DISORDERS^3^64
 ;;^UTILITY(U,$J,358.4,777,0)
 ;;=COUNSELING & SCREENING^4^64
 ;;^UTILITY(U,$J,358.4,778,0)
 ;;=GENITOURINARY NEOPLASMS^5^64
 ;;^UTILITY(U,$J,358.4,779,0)
 ;;=GI CANCER^6^64
 ;;^UTILITY(U,$J,358.4,780,0)
 ;;=HEAD/NECK/LUNG CANCER^7^64
 ;;^UTILITY(U,$J,358.4,781,0)
 ;;=HEMOGLOBINOPATHIES^9^64
 ;;^UTILITY(U,$J,358.4,782,0)
 ;;=LYMPHOID NEOPLASMS^10^64
 ;;^UTILITY(U,$J,358.4,783,0)
 ;;=METASTATIC SITES^11^64
 ;;^UTILITY(U,$J,358.4,784,0)
 ;;=MISC. NEOPLASMS^12^64
 ;;^UTILITY(U,$J,358.4,785,0)
 ;;=MYELOID NEOPLASMS/DISORDERS^13^64
 ;;^UTILITY(U,$J,358.4,786,0)
 ;;=PERSONAL HX OF CANCER^15^64
 ;;^UTILITY(U,$J,358.4,787,0)
 ;;=OTHER^14^64
 ;;^UTILITY(U,$J,358.4,788,0)
 ;;=HEMATOLOGICAL^8^64
 ;;^UTILITY(U,$J,358.4,789,0)
 ;;=SYMPTOMS^16^64
 ;;^UTILITY(U,$J,358.4,790,0)
 ;;=TREATMENT^17^64
 ;;^UTILITY(U,$J,358.4,791,0)
 ;;=HOSPICE CARE SUPERVISION^2^65
 ;;^UTILITY(U,$J,358.4,792,0)
 ;;=PROLONGED SERVICES^3^65
 ;;^UTILITY(U,$J,358.4,793,0)
 ;;=ADVANCE CARE PLANNING^1^65
 ;;^UTILITY(U,$J,358.4,794,0)
 ;;=INPATIENT CONSULTATIONS^1^66
 ;;^UTILITY(U,$J,358.4,795,0)
 ;;=INITIAL INPATIENT CARE^2^66
 ;;^UTILITY(U,$J,358.4,796,0)
 ;;=SUBSEQUENT INPATIENT CARE^3^66
 ;;^UTILITY(U,$J,358.4,797,0)
 ;;=DISCHARGE/PRONOUNCEMENT^4^66
 ;;^UTILITY(U,$J,358.4,798,0)
 ;;=NH INITIAL INPATIENT CARE^5^66
 ;;^UTILITY(U,$J,358.4,799,0)
 ;;=NH SUBSEQUENT INPATIENT CARE^6^66
 ;;^UTILITY(U,$J,358.4,800,0)
 ;;=NH DISCHARGE/PRONOUNCEMENT^7^66
